Condition
Rotator Cuff Injury: Options and What the Evidence Actually Shows
Partial tears and tendinopathy are where orthobiologics are most often discussed. Full-thickness tears are usually a repair conversation.
Anatomy and clinical context
The rotator cuff compresses and rotates the humeral head. Tears range from partial articular-sided fraying to massive retracted full-thickness tears.
PT restores function for many partial tears. Repair timing depends on tear size, fatty infiltration, and patient goals.
Illustration of the shoulder and rotator cuff
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Physical therapy and activity modification.
- Step 2
Injections
Corticosteroid for bursitis flares; PRP/orthobiologics in selected partial tears.
- Step 3
Surgery
Arthroscopic or open cuff repair; reverse arthroplasty for irreparable cuff arthropathy.
Where cell therapy fits
Orthobiologic evidence in cuff disease is protocol-dependent. Demand clarity on tear type before any regenerative sales pitch.
- Partial tears ≠ full-thickness tears — treatment intent differs.
- Same-day products remain dose-limited.
- Banking supports future expanded autologous use if your physician's protocol needs it.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Cartistem
Approved product (Korea) · Regulatory approval (2012)
Culture-expanded allogeneic MSC product approved in Korea with structural signal in cartilage repair settings.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.